about
Autophagy in acute leukemias: a double-edged sword with important therapeutic implicationsTherapeutic targeting of Polo-like kinase-1 and Aurora kinases in T-cell acute lymphoblastic leukemia.Targeting the liver kinase B1/AMP-activated protein kinase pathway as a therapeutic strategy for hematological malignancies.Targeting signaling pathways in T-cell acute lymphoblastic leukemia initiating cells.Therapeutic potential of targeting mTOR in T-cell acute lymphoblastic leukemia (review).Current treatment strategies for inhibiting mTOR in cancer.Advances in understanding the acute lymphoblastic leukemia bone marrow microenvironment: From biology to therapeutic targeting.PLCβ1a and PLCβ1b selective regulation and cyclin D3 modulation reduced by kinamycin F during k562 cell differentiation.K562 cell proliferation is modulated by PLCβ1 through a PKCα-mediated pathway.Increased NGAL (Lnc2) expression after chemotherapeutic drug treatment.Activity of the selective IκB kinase inhibitor BMS-345541 against T-cell acute lymphoblastic leukemia: involvement of FOXO3a.Cytotoxic activity of the novel Akt inhibitor, MK-2206, in T-cell acute lymphoblastic leukemia.Enhancing the effectiveness of nucleoside analogs with mTORC1 blockers to treat acute myeloid leukemia patients.Activity of the pan-class I phosphoinositide 3-kinase inhibitor NVP-BKM120 in T-cell acute lymphoblastic leukemia.Cytotoxic activity of the casein kinase 2 inhibitor CX-4945 against T-cell acute lymphoblastic leukemia: targeting the unfolded protein response signaling.Temsirolimus, an mTOR inhibitor, in combination with lower-dose clofarabine as salvage therapy for older patients with acute myeloid leukaemia: results of a phase II GIMEMA study (AML-1107)
P50
Q26828544-46351DA5-D15E-4655-A913-A28FBAB75B22Q33952803-87C77048-FA36-4525-843F-F29B7110BFF1Q38017727-01E30B2D-423F-4E79-96ED-8B6399389827Q38211159-A38E19B6-3259-4F47-8341-C8C2286C6C12Q38223508-97C2DBD6-908A-4A5F-8870-EA34FA6BB3D2Q38286529-2073FA69-01AD-49AA-A038-4A195CB0798CQ38579553-945D9DFB-1675-4730-8029-30D810E4EB46Q38962513-D1ED55B4-C63A-4C41-B00C-3B5ECDDD24B1Q39154752-8A12606B-BD02-4CA0-B0DB-895A156423EEQ39257895-F501ABF8-0703-4BA8-9D9E-6BB9EFB719FEQ39328413-96E78814-3F8F-44CE-ADD3-AF8CBDDD6B56Q39344848-F6301BF8-44B9-4DB4-B889-F744E8BF0971Q42541266-D4C42F39-3EF8-4B6C-9D34-A491C6754853Q44498168-4E01972A-552D-4A59-8F85-011C6B77ACEDQ46085978-D79EAD67-ECDA-4A43-99D5-9C866D9B2397Q82498689-2504578F-2E32-487E-BCFA-3E7DA482B520
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Francesca Chiarini
@ast
Francesca Chiarini
@en
Francesca Chiarini
@es
Francesca Chiarini
@nl
type
label
Francesca Chiarini
@ast
Francesca Chiarini
@en
Francesca Chiarini
@es
Francesca Chiarini
@nl
prefLabel
Francesca Chiarini
@ast
Francesca Chiarini
@en
Francesca Chiarini
@es
Francesca Chiarini
@nl
P106
P31
P496
0000-0002-4568-3189